Doc-in-a-Box: Platform for Pre-Symptomatic Diagnosis of Illness and Disease

Printer-friendly versionPDF version


Doc in a box is a collection of printed microarrays incorporated into an at-home testing unit that can test protein peptides in the blood to determine a patient’s current state of health.  The doc-in-a-box will use these microarrays to accurately monitor the patient’s biosignatures to provide baseline levels of the patient's health[1].  The above illustrates the mapping, separation, screening and averaging of the blood plasma protein peptide transferrin, performed by using a novel synthetic protein affinity reagent made from a synthetic DNA Scaffold incorporated into these microarrays[2]

Once baseline levels are obtained, the doc-in-a-box can track the patient’s altered states of blood proteins against baseline protein peptide levels to give a customized daily report on the patient’s health.  This will allow patients to know if they are ill, prone to disease, or susceptible to chronic conditions before physical signs are present.  In essence, the doc-in-a-box will allow for personalized preventative diagnosis, reducing the damage done by illness and disease and reducing the costs of healthcare.  Additionally, this technology would open up opportunities for personalized medicine that can incorporate daily blood assay results into very specific daily doses of medicine.



Product Name: 

Development Stage: 

Key Words: 




This product has the potential to allow for monitoring of biomarkers and biosignatures at home through instantaneous blood testing in an mini autonomous laboratory.






Benefit Summary: 

The Doc-in-a-Box will allow for personalized preventative medicine at home, reducing healthcare costs, reducing acute chronic disease diagnosis, and giving patients more control of their health.


Risk Summary: 

The risks in this technology are very low since the DNA in the microarrays are synthetic and the system only takes a small sample of the patient’s blood. The system is non-invasive and does not administer treatment. Additionally, the system uses no nanomaterials, on active nanoscale biological systems for diagnosis.

Risk Characterization: 

Risk Assessment: 





Challenge Area: